Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 49, Issue 10, 2011, Pages 587-593

  Yuan, M K ^a   Chang, C Y ^b   Chang, S C ^a   Chang, S J ^c   Tang, G J ^a   Wei, Y F ^d   Liu, Y C ^a   Chen, C Y ^a   Yu, C J ^e  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c ALETHEIA UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Gefitinib; Interstitial lung disease; Non small cell lung cancer

Indexed keywords

GEFITINIB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; EARLY DIAGNOSIS; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLUS CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD; OXYGEN SATURATION; PROGNOSIS; THORAX RADIOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; QUINAZOLINES; RADIOGRAPHY, THORACIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 80053597694     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP201566     Document Type: Article

References (23)

1. Camus P, Fanton A, Bonniaud P, Camus C, Foucher P. Interstitial lung disease induced by drugs and radiation. Respiration. 2004; 71: 301-326. doi: 10.1159/000079633 PubMed (Pubitemid 39179164)
2. Gazdar AF. Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer Metastasis Rev. 2010; 29: 37-48. doi: 10.1007/s10555-010-9201-z PubMed
3. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008; 358. 1160-1174. doi: 10.1056/NEJMra0707704 PubMed
4. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, et al Spanish Lung Cancer Group. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009; 361: 958-967. doi: 10.1056/NEJMoa0904554 PubMed
5. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361: 947-957. doi: 10.1056/NEJMoa0810699 PubMed
6. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet. 2003; 361: 137-139. doi:10.1016/S0140-6736(03)12190-3 PubMed (Pubitemid 36092019)
7. Nakagawa M, Nishimura T, Teramukai S, Tada H, Tanaka F, Yanagihara K, Furuse K, Wada H, Fukushima M. Interstitial lung disease in gefitinib-treated Japanese patients with non-small cell lung cancer - a retrospective analysis: JMTO LCO3-02. BMC Res Notes. 2009; 2: 157. doi: 10.1186/1756-0500-2-157 PubMed
8. Jiang H. Overview of gefitinib in non-small cell Lung cancer: an Asian perspective. Jpn J Clin Oncol. 2009; 39: 137-150. doi: 10.1093/jjco/hyn139 PubMed
9. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Ichinose Y, Tsuboi M, Yokota S, Nakagawa K, Suga M, Jiang H, Itoh Y, Armour A, Watkins C, Higenbottam T, Nyberg F; Japan Thoracic Radiology Group. Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med. 2008; 177: 1348-1357. doi: 10.1164/rccm.200710-1501OC PubMed (Pubitemid 351860912)
10. Marchetti A, Martella C, Felicioni L, Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli F, Mezzetti A, Cuccurullo F, Sacco R, Buttitta F. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol. 2005; 23: 857-865. doi: 10.1200/JCO.2005.08.043 PubMed (Pubitemid 46224186)
11. Camus P, Kudoh S, Ebina M. Interstitial lung disease associated with drug therapy. Br J Cancer. 2004; 91 (Suppl 2): 518-523. doi: 10.1038/sj.bjc.6602063 PubMed
12. Akoun GM, Cadranel JL, Milleron BJ, D'Ortho MP, Mayaud CM. Bronchoalveolar lavage cell data in 19 patients with drug-associated pneumonitis (except amiodarone). Chest. 1991; 99: 98-104. doi: 10.1378/chest.99.1.98 PubMed
13. Sitbon O, Bidel N, Dussopt C, Azarian R, Braud ML, Lebargy F, Fourme T, De Blay F, Piard F, Camus P. Minocycline pneumonitis and eosinophilia. A report on eight patients. Arch Intern Med. 1994; 154: 1633-1640. doi: 10.1001/archinte.154.14.1633 PubMed
14. Endo M, Johkoh T, Kimura K, Yamamoto N. Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group. Lung Cancer. 2006; 52: 135-140. doi: 10.1016/j.lungcan.2006.02.002 PubMed
15. Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf. 2005; 28: 103-113. doi: 10.2165/00002018-200528020-00002 PubMed (Pubitemid 40321766)
16. Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, Johnson DH, Laskin JL, Masters G, Milton D, Nordquist L, Pfister DG, Piantadosi S, Schiller JH, Smith R, Smith TJ, Strawn JR, Trent D, Giaccone G; American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009; 27: 6251-6266. doi: 10.1200/JCO.2009.23.5622 PubMed
17. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res. 2004; 10: 1212-1218. doi: 10.1158/1078-0432.CCR-03- 0564 PubMed (Pubitemid 38365209)
18. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto K, Ariyoshi Y, Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol. 2006; 24: 2549-2556. doi:10.1200/JCO.2005.04.9866 PubMed (Pubitemid 46630633)
19. Padley SP, Adler B, Hansell DM, Müller NL. High-resolution computed tomography of drug-induced lung disease. Clin Radiol. 1992; 46: 232- 236. doi: 10.1016/S0009-9260(05)80161-8 PubMed
20. Akira M, Ishikawa H, Yamamoto S. Drug-induced pneumonitis: thin-section CT findings in 60 patients. Radiology. 2002; 224: 852-860. doi:10.1148/radiol. 2243011236 PubMed (Pubitemid 34919824)
21. Cleverley JR, Screaton NJ, Hiorns MP, Flint JD, Müller ML. Drug-induced lung disease: high-resolution CT and histological findings. Clin Radiol. 2002; 57: 292-299. doi: 10.1053/crad.2001.0792 PubMed (Pubitemid 36503366)
22. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, et al North-East Japan Study Group. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010; 362: 2380-2388. doi: 10.1056/NEJMoa0909530 PubMed
23. Moiseyenko VM, Procenko SA, Levchenko EV, Barchuk AS, Moiseyenko FV, Iyevleva AG, Mitiushkina NV, Togo AV, Semionov II, Ivantsov AO, Matsko DE, Imyanitov EN. High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma. Onkologie. 2010; 33: 231-238. doi: 10.1159/000302729 PubMed